Tofacitnib for the Treatment of Alopecia Areata and Variants
Completed
Yale University
Phase 2
2014-07-01
The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus
kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia
areata and its variants.
Tofacitinib for the Treatment of Alopecia Areata and Its Variants
Completed
Stanford University
N/A
2014-12-01
The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus
kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia
areata and its variants.
Study of Tofacitinib in Refractory Dermatomyositis
Completed
Pfizer
Phase 1
2017-01-01
The purpose of this study is to obtain preliminary data regarding the safety and efficacy of
Janus kinase (JAK) inhibitor, tofacitinib, in adults with active, treatment-refractory
dermatomyositis.
Study of Tofacitinib in Refractory Dermatomyositis
Completed
Johns Hopkins University
Phase 1
2017-01-01
The purpose of this study is to obtain preliminary data regarding the safety and efficacy of
Janus kinase (JAK) inhibitor, tofacitinib, in adults with active, treatment-refractory
dermatomyositis.
Tofacitinib Citrate Topical Gel 3.2% FDA BA Bridging Study
Recruiting
TWi Biotechnology, Inc.
Phase 1
2020-10-14
This is a Phase 1, single center, open-label, fixed sequence, two-period pharmacokinetic (PK)
study to evaluate the safety and relative systemic bioavailability of topical and oral
tofacitinib formulations in approximately 14 healthy subjects. Participants will receive a
single oral dose of tofacitinib 5 mg tablet in Period 1 of the study followed by a 7-day
washout period. In Period 2, participants will receive repeat administration of Tofacitinib
Citrate Topical Gel 3.2% BID for 14 days.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
